Neu­roster­ix emerges with $63M to fol­low Karuna, Cerev­el

Small Swiss biotech Ad­dex Ther­a­peu­tics is trans­fer­ring its neu­ro­science as­sets and its al­losteric mod­u­la­tor plat­form to a new biotech that has picked up $63 mil­lion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER